Corcept Therapeutics CORT Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $47.34M-64.7% | $99.65M-29.4% | $106.11M-25.2% | $133.66M+6.1% | $133.99M+13.5% | ||
| $1.29M+13.0% | $1.15M+44.5% | $1.14M+56.7% | $1.17M+82.2% | $1.14M+14.8% | ||
| $85.71M+22.6% | $84.5M+37.7% | $80.53M+39.7% | $73.75M+35.6% | $69.94M+37.0% | ||
| —— | —— | —— | -$50.53M-50.2% | -$46.73M-56.1% | ||
| —— | —— | —— | —— | —— | ||
| $11.84M— | $7.96M— | —— | —— | —— | ||
| —— | —— | —— | —— | $15.41M+1,176% | ||
| —— | —— | $27.88M— | $30.34M— | $24.46M— | ||
| —— | —— | —— | —— | —— | ||
| $120.45M-32.8% | $142M-28.4% | $163.61M+13.8% | $182.42M+47.8% | $179.31M+44.0% | ||
| $308K-86.5% | $211K-90.3% | $282K-86.3% | $1.92M+323% | $2.28M+1,537% | ||
| —— | —— | $17.24M+118% | -$41.44M— | -$171.76M— | ||
| $145.48M+241% | $172.92M+1,004% | $172.92M+1,004% | $142.16M+3,495% | $42.62M+8,854% | ||
| $62.88M+72.9% | $72.94M+227% | $43.39M+166% | $46.89M+382% | $36.37M+278% | ||
| -$179.8M-166% | -$220.37M-677% | -$193.71M-714% | -$168.39M-2,448% | -$67.61M+55.0% | ||
| —— | —— | —— | $1.57M— | —— | ||
| —— | —— | —— | —— | -$59.93M— | ||
| —— | $12.97M-78.5% | $24.79M-56.6% | $36.62M-32.1% | $48.44M-4.6% | ||
| —— | $5.1M-53.3% | $6.56M-37.4% | $8.02M-20.1% | $9.48M-1.1% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | $27.88M— | $30.34M— | $24.46M— | ||
| —— | —— | —— | —— | —— | ||
| $10.44M+67.5% | $9.62M+76.2% | $8.69M+81.0% | $7.81M+85.2% | $6.23M+30.6% | ||
| —— | $12.97M-78.5% | $24.79M-56.6% | $36.62M-32.1% | $48.44M-4.6% | ||
| $23.64M-4.1% | $24.56M+15.9% | $24.81M+45.8% | $27.12M+19.8% | $24.66M+14.2% | ||
| $120.15M-32.1% | $141.79M-27.7% | $163.32M+15.2% | $180.5M+46.8% | $177.03M+42.4% | ||
| $120.15M-32.1% | $141.79M-27.7% | $163.32M+15.2% | $180.5M+46.8% | $177.03M+42.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Corcept Therapeutics generate?
- Corcept Therapeutics (CORT) generated $120.5M in operating cash flow over the trailing twelve months.
- What is Corcept Therapeutics's free cash flow?
- After $308.0K of capital expenditures, Corcept Therapeutics's free cash flow was $120.1M over the trailing twelve months, down 32.1% year over year.
- Where does Corcept Therapeutics's cash flow data come from?
- Every line is extracted from Corcept Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
